Zinc and the Common Cold: What the Cochrane Review Found

What the review covered

The current Cochrane review was published in May 2024 by Nault and colleagues. It searched six databases and two trial registries and found 34 randomized trials with 8,526 participants: 19 treatment trials with 2,419 people and 15 prevention trials with 6,107. Twenty-two enrolled adults and 12 enrolled children. The largest share ran in the United States, the rest across 13 countries. Three decades of research sit behind that. The authors rated their confidence in the evidence as mostly low to very low. Three problems pulled it down. Some trials didn't describe randomization, so group differences could reflect who landed in each arm. Delivery methods varied enormously. Outcomes were measured differently, which makes pooling a rough exercise.

What the treatment trials found

On prevention, the pooled estimate barely moves. Across 9 trials with 1,449 people the risk ratio for developing a cold was 0.93 (95% CI 0.85 to 1.01), rated low certainty. The mean number of colds over 5 to 18 months differed by 0.90 (95% CI 1.93 to 0.12), with heterogeneity at I² = 96%. On treatment, the pooled difference in mean duration came to 2.37 days (95% CI 4.21 to 0.53) across 8 trials with 972 people, against an average seven day duration in the placebo groups. That's a difference on paper, and the authors still rated certainty low because I² hit 97%.

Severity is where the record thins out. Two trials with 261 people measured global symptom severity, and the pooled standardized mean difference was 0.03 (95% CI 0.56 to 0.50). The authors called the result uncertain.

Dose and formulation

The doses in these trials sit far above normal dietary intake.

Zinc gluconate was given at 45 to 276 mg a day for 4.5 to 21 days. For reference, the Recommended Dietary Allowance is 11 mg a day for adult men and 8 mg for adult women, and the tolerable upper intake level is 40 mg.

Formulation matters more than most people assume. The thinking behind zinc lozenges is that free ionic zinc released in the mouth and throat interferes with viral replication right there, not that blood zinc climbs. Anything in the lozenge that binds zinc ions, citric acid being the usual example, can block that release.

Hemilä tested this in a 2017 JRSM Open analysis comparing zinc acetate with zinc gluconate. Above 75 mg a day of elemental zinc the two salts gave broadly similar reductions in duration. Below that the effect collapsed.

Why early initiation comes up so often

The trials that found a difference generally had people start within a day of their first symptom. In a 2016 individual patient data analysis in the British Journal of Clinical Pharmacology, Hemilä and colleagues pooled three zinc acetate trials with 199 patients. The one stage estimate was 2.73 days shorter (95% CI 1.8 to 3.3 days) and the two stage estimate was 2.94 days (95% CI 2.1 to 3.8 days). Age, sex, allergy status, smoking, and baseline severity didn't change the result.

That timing condition isn't a footnote.

If the mechanism is interference at the point of entry, day three is a different intervention from day one. Several trials that found nothing started later.

Adverse effects

Side effects are the best established part of this evidence base, and they run against the benefit.

For treatment, non-serious adverse events were more common with zinc, at a risk ratio of 1.34 (95% CI 1.15 to 1.55) across 16 trials with 2,084 people, rated moderate certainty.

Taste irregularities and stomach upset were the most frequent complaints. No treatment trial reported serious adverse events.

For prevention, the numbers are murkier.

Non-serious adverse events came in at a risk ratio of 1.11 (95% CI 0.84 to 1.47) across 7 trials with 1,517 people, rated very low certainty. Serious adverse events came in at 1.67 (95% CI 0.78 to 3.57) across 3 trials with 1,563 people. Both intervals cross 1.0, so neither is a finding.

Intranasal zinc sits apart. The review found no reported cases of anosmia in those trials but said the information on specific harms is uncertain. Guidance for family physicians lists intranasal zinc among interventions where harms outweigh benefits, because the loss of smell can be permanent.

Where the analyses disagree

This is a real disagreement in the literature, not a case of a missing study.

Hemilä's own pooled analyses restrict inclusion to zinc acetate lozenges at 80 to 92 mg a day started early, and they give larger and more consistent effects than the Cochrane review does. A 2017 reanalysis of the same three trials using survival methods estimated that zinc patients recovered 3.1 times faster, with 70% recovered by day five against 27% on placebo. The Cochrane review casts a wider net. It takes every salt, doses from 45 mg upward, nasal sprays alongside lozenges, and children alongside adults. With that much variation in one pool, heterogeneity hits 97% and the authors decline to treat the average as solid.

Then Hemilä ran his own trial and it came back negative. Published in BMJ Open in 2020, it randomized 253 city employees in Finland to keep lozenges on hand. Of those, 88 caught a cold and 87 were analyzed. Participants dissolved six lozenges a day for five days, supplying 78 mg of elemental zinc daily. There was no difference in recovery, at a rate ratio of 0.68 (95% CI 0.42 to 1.08), and over the two days after treatment stopped the zinc group recovered more slowly. Thirty-seven percent of zinc users reported no adverse effects, against 69% on placebo.

The researcher whose pooled work gives the most favorable numbers also ran the trial that failed to confirm it, and said so in print.

Frequently asked questions

Does zinc stop you from catching a cold?

The pooled prevention trials say it makes little or no difference. The risk ratio was 0.93 with a confidence interval that just touches 1.0.

How much zinc did the trials use?

Zinc gluconate studies ranged from 45 to 276 mg of elemental zinc a day, and zinc acetate studies used 80 to 92 mg a day. Those are study protocols, not amounts to copy.

Why does the salt form matter?

The proposed mechanism depends on free ionic zinc reaching the mouth and throat. Citrate and other additives bind zinc ions and stop that release, one explanation for why those trials came back empty.

Is a bad taste the only downside?

Taste problems and nausea are the common ones. Long term high intake also competes with copper absorption.

What about zinc nasal sprays?

Guidance for family physicians lists them as harms that outweigh benefits, given reports of permanent smell loss.

---

This article is for general information only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Talk with your health care provider before using zinc for colds, especially if you take prescription medication.

Sources

• Nault D, Machingo TA, Shipper AG, et al. Zinc for prevention and treatment of the common cold. Cochrane Database Syst Rev. 2024;(5):CD014914.
• Hemilä H, Petrus EJ, Fitzgerald JT, Prasad A. Zinc acetate lozenges for treating the common cold: an individual patient data meta-analysis. Br J Clin Pharmacol. 2016;82(5):1393-1398.
• Hemilä H, Fitzgerald JT, Petrus EJ, Prasad A. Zinc acetate lozenges may improve the recovery rate of common cold patients: an individual patient data meta-analysis. Open Forum Infect Dis. 2017.
• Hemilä H, Haukka J, Alho M, Vahtera J, Kivimäki M. Zinc acetate lozenges for the treatment of the common cold: a randomised controlled trial. BMJ Open. 2020;10(1):e031662.
• NIH Office of Dietary Supplements. Zinc Fact Sheet for Health Professionals.